Table 2.
Evaluation of menstrual changes according to COVID-19 vaccine type.
| Menstrual change* | COVID-19 vaccine type | Total n (%) |
P ** | ||
|---|---|---|---|---|---|
| Sinovac n (%) |
BioNTech n (%) |
Sinovac + BioNTech n (%) |
|||
| Menstrual delay | 15 (28.3%) | 133 (30.0%) | 28 (31.5%) | 176 (30.0%) | .92 |
| 1–7 d | 12 (22.6%) | 69 (15.6%) | 15 (16.9%) | 96 (16.4%) | |
| 8–14 d | 1 (1.9%) | 27 (6.1%) | 6 (6.7%) | 34 (5.8%) | |
| 15 d or more | 2 (3.8%) | 37 (8.3%) | 7 (7.9%) | 46 (7.8%) | |
| Prolongation of menstrual duration | 17 (32.1%) | 97 (21.8%) | 18 (20.2%) | 132 (22.5%) | .20 |
| 1–2 d | 6 (11.3%) | 41 (9.2%) | 7 (7.9%) | 54 (9.2%) | |
| 3 d or more | 11 (20.8%) | 56 (12.6%) | 11 (12.3%) | 78 (13.3%) | |
| Intermenstrual bleeding | 5 (9.4%) | 46 (10.4%) | 8 (9.0%) | 59 (10.1%) | .91 |
| Heavy bleeding | 9 (17.0%) | 40 (9.0%) | 5 (5.6%) | 54 (9.2%) | .06 |
| Decrease in menstrual bleeding | 3 (5.7%) | 31 (7.0%) | 1 (1.1%) | 35 (6.0%) | .11 |
| Early menstruation | 2 (3.8%) | 12 (2.7%) | 2 (2.2%) | 16 (2.7%) | .76 |
| No change | 20 (37.7%) | 209 (47.1%) | 46 (51.7%) | 275 (46.9%) | .27 |
| Total | 53 (100.0%) | 444 (100.0%) | 89 (100.0%) | 586 (100.0%) | |
*
Multiple responses were obtained.
**
Chi-square test was used for the statistical analysis.